Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics (UTHR) Form 144 summary: This notice reports a proposed sale of 4,000 common shares through TD Securities (USA) LLC with an aggregate market value of $1,891,277.50, listing an approximate sale date of 09/30/2025 on NASDAQ. The securities were originally acquired on 03/15/2016 under an executive deferred compensation arrangement from Martine Rothblatt, totaling 294,000 shares acquired at that time. The filing also discloses prior sales by Martine Rothblatt in September 2025 totaling 64,000 shares sold across multiple dates, with daily gross proceeds shown per trade. Outstanding shares are listed as 45,230,000, providing context for the reported transactions.
UNITED THERAPEUTICS (UTHR) Form 144: This notice reports a proposed sale of 4,000 common shares through TD Securities (USA) LLC with an aggregate market value of $1,702,446.76 and shows 60,000 shares sold by Martine Rothblatt across multiple dates in September 2025. The filing records that 294,000 shares were originally acquired on 03/15/2016 under an executive deferred compensation arrangement and that the acquisition involved exercised vested options paid via common shares. The issuer has approximately 45,230,000 shares outstanding. The filer certifies no undisclosed material adverse information.
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), reported option exercises and share sales under a pre-arranged 10b5-1 plan dated May 2, 2025. On 09/25/2025 and 09/26/2025 she exercised 4,000 options each day at a $120.26 exercise price, resulting in 8,000 underlying shares acquired. Concurrently she sold multiple blocks totaling 8,000 shares across the two days at weighted-average prices in the high $420s to low $430s, with reported weighted averages of $429.0678, $430.2525 and $431.9026 for specific trades. Post-transactions she directly owns 130 shares and indirectly holds large positions through spouse and family trusts totaling several hundred thousand shares.
United Therapeutics insider sale notice: This Form 144 reports that Martine Rothblatt proposes to sell 4,000 shares of United Therapeutics common stock through TD Securities on 09/26/2025 with an aggregate market value of $1,712,811.00. The filing shows these shares were acquired on 03/15/2016 as part of an executive deferred compensation arrangement totaling 294,000 shares and that payment was made by exercising vested options and delivering common shares. The filing also lists the insider's market sales over the past three months totaling 56,000 shares across multiple dates from 09/09/2025 to 09/25/2025, with daily gross proceeds shown per trade. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.
Causey Christopher, a director of United Therapeutics (UTHR), reported insider transactions on 09/24/2025. He exercised a stock option to acquire 1,000 shares at an exercise price of $119.76 and simultaneously sold 1,000 shares at $440 per share. After the transactions, the filing reports 4,865 shares beneficially owned directly and 9,320 shares represented by derivative holdings.
Rothblatt Martine A, Chairperson & CEO of United Therapeutics (UTHR), reported exercises and sales of company stock options under a pre-arranged 10b5-1 trading plan entered May 2, 2025. On 09/23/2025 and 09/24/2025 she exercised a total of 8,000 options at an exercise price of $120.26 each, and sold shares in multiple trades at weighted-average prices ranging from about $416.51 to $436.84 depending on the tranche. Following the reported transactions she directly owns smaller blocks of shares and continues to have significant indirect holdings through family trusts and spouse-controlled accounts totaling the amounts listed on the form. The option tranche referenced totals 294,000 options expiring March 15, 2026, and the 10b5-1 plan runs until that tranche is exhausted or December 31, 2025.
UNITED THERAPEUTICS (UTHR) Form 144 filing: An insider, Martine Rothblatt, notified the sale of 4,000 common shares through TD Securities with an approximate aggregate market value of $1,723,659, and the filing lists the issuer's outstanding common shares as 45,230,000. The securities reported were originally acquired on 03/15/2016 as part of an executive deferred compensation arrangement totaling 294,000 shares, with payment made via exercised vested options. The filing also discloses multiple prior open-market sales by the same person during September 2025, totaling 52,000 shares across listed dates and generating the gross proceeds shown per trade. The filer certifies no undisclosed material adverse information.
The filing is a Form 144 notice for proposed sale of 1,000 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on 09/24/2025 with an aggregate market value of $440,000.00. The securities were acquired and paid for on 09/24/2025 by stock option exercise. The filing shows 45,226,262 shares outstanding for the issuer. The notice discloses prior sales by an identified seller of 3,000 shares on 09/02/2025 for gross proceeds of $1,269,630.00. The signer represents they have no material nonpublic information regarding the issuer.
Form 144 filed for United Therapeutics (UTHR) reporting proposed and recent insider sales by Martine Rothblatt. The notice lists a proposed sale of 4,000 common shares through TD Securities on 09/24/2025 with an aggregate market value of $1,736,408.50 and shows the company has 45,230,000 shares outstanding. The filer records the original acquisition of the securities on 03/15/2016 under an executive deferred compensation arrangement, noting 294,000 shares acquired and that payment involved exercised options and common shares. The filing also discloses multiple sales by Martine Rothblatt from 09/09/2025 through 09/23/2025 totaling 48,000 common shares with gross proceeds listed per trade.
United Therapeutics insider activity: Michael Benkowitz, President and COO, exercised stock options and sold the resulting shares on 09/22/2025 under a Rule 10b5-1 trading plan entered into June 3, 2025. The filing shows exercise of 14,625 options at $135.42 and sale of the resulting 14,625 shares at $416.3535, and exercise of 7,875 options at $146.03 with sale of those 7,875 shares at $416.3535. Following the sales, the reported beneficial ownership from the two trusts tied to the reporting person shows 0 shares for the sold lots. The transactions were executed through trusts of which the reporting person is a beneficiary or trustee, and were signed under power of attorney on 09/23/2025.
United Therapeutics insider activity: Michael Benkowitz, President and COO, exercised stock options and sold the resulting shares on 09/22/2025 under a Rule 10b5-1 trading plan entered into June 3, 2025. The filing shows exercise of 14,625 options at $135.42 and sale of the resulting 14,625 shares at $416.3535, and exercise of 7,875 options at $146.03 with sale of those 7,875 shares at $416.3535. Following the sales, the reported beneficial ownership from the two trusts tied to the reporting person shows 0 shares for the sold lots. The transactions were executed through trusts of which the reporting person is a beneficiary or trustee, and were signed under power of attorney on 09/23/2025.